XML 75 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative Arrangements - Narrative (Details)
course in Thousands, $ in Millions
1 Months Ended 12 Months Ended
Dec. 31, 2021
USD ($)
course
Nov. 30, 2021
course
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
course
market
country
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Other intangibles, net $ 22,933     $ 22,933 $ 14,101  
Amortization       $ 1,636 1,817 $ 1,695
Number of markets (more than) | market       30    
Number of low and middle income countries (more than) | country       100    
Supply Commitment to United States            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Quantity committed (in courses) | course 3,100          
Quantity delivered (in courses) | course       888    
Supply Commitment to Japan            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Quantity committed (in courses) | course 1,600          
Quantity delivered (in courses) | course       200    
Supply Commitment to United Kingdom            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Quantity committed (in courses) | course   2,230        
Quantity delivered (in courses) | course       152    
Supply Commitment to United Nations Children's Fund            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Quantity committed (in courses) | course       3,000    
License            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Other intangibles, net $ 3,368     $ 3,368 3,553  
Lenvima | License            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Other intangibles, net 1,000     1,000    
Adempas | Licenses and other            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Intangible assets 806     806    
Verquvo            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Amortization       153    
Verquvo | Licenses and other            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Intangible assets 68     68    
Lynparza | License            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Other intangibles, net 1,100     1,100    
Eisai            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
License option payment related to collaborative arrangement     $ 125      
Eisai | Lenvima | Sales-Based Milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments made to collaborative partner       200 500 50
Eisai | Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments accrued 600     600    
Accrued regulatory approval milestone payment 25     25    
Potential Future Milestone Payments Sales-Based 2,600     2,600    
Potential Future Milestone Payments Regulatory 25     25    
Eisai | Lenvima | Regulatory Milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments made to collaborative partner       75 10  
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments accrued 400     400    
Liabilities 400     400    
Bayer AG | Adempas | Sales-Based Milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments made to collaborative partner         375  
AstraZeneca | Lynparza | Sales-Based Milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments made to collaborative partner         550 200
AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments accrued 400     400    
Potential Future Milestone Payments Sales-Based 2,700     2,700    
Potential Future Milestone Payments Regulatory $ 1,400     $ 1,400    
AstraZeneca | Lynparza | Regulatory Milestones            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments made to collaborative partner         $ 160 $ 60